Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism

2021 ◽  
Author(s):  
Alessio Basolo ◽  
Antonio Matrone ◽  
Rossella Elisei ◽  
Ferruccio Santini
Keyword(s):  
Thyroid Hormone ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Thyroid Function ◽  
Kinase Inhibitors ◽  
Hormone Metabolism ◽  
Thyroid Hormone Metabolism

Thyroid function and thyroid hormone metabolism in elderly people low T3-syndrome in old age?

1981 ◽  
Vol 59 (7) ◽  
pp. 315-323 ◽  
Author(s):  
J. Herrmann ◽  
E. Heinen ◽  
H. J. Kr�ll ◽  
K. H. Rudorff ◽  
H. L. Kr�skemper
Keyword(s):  
Thyroid Hormone ◽  
Elderly People ◽  
Old Age ◽  
Thyroid Function ◽  
Hormone Metabolism ◽  
Low T3 Syndrome ◽  
Thyroid Hormone Metabolism ◽  
Low T3

scholarly journals Antiepileptic Drugs and Thyroid Hormone Homeostasis: Literature Review and Practical Guideline

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A824-A824
Author(s):  
Anne Maria Rochtus ◽  
Dorien Herijgers ◽  
Katrien Jansen ◽  
Brigitte Decallonne
Keyword(s):  
Thyroid Hormone ◽  
Thyroid Function ◽  
Cortical Excitability ◽  
System Development ◽  
Intractable Epilepsy ◽  
Nervous System Development ◽  
Hormone Metabolism ◽  
Cross Sectional ◽  
Thyroid Hormone Metabolism ◽  
Practical Guideline

Abstract Thyroid hormones play an essential role in central nervous system development, normal physiological brain function and repairing mechanisms. On one hand, thyroid hormone alterations influence cortical excitability and on the other hand anti-epileptic drugs (AEDs) are associated with alterations in thyroid hormone metabolism. Although this interaction has long been described, and epilepsy is a common and chronic neurological disease, studies describing the interplay are often small and retrospective. We performed a systematic review of the current literature on epilepsy, AED therapy and thyroid hormone metabolism. Forty-seven studies were included. Most studies were retrospective cross-sectional studies (n=25) and investigated thyroid function alterations in patients on older AEDs such as phenobarbital, phenytoin, carbamazepine and valproic acid. Overall, almost one third of patients with epilepsy had subclinical hypothyroidism, especially patients on valproate and carbamazepine. Studies with patients receiving polytherapy are scarce, but reported a higher risk for hypothyroidism in patients with older age, female sex, longer duration of epilepsy, intractable epilepsy and polytherapy. Studies on newer AEDs are also scarce and further studies essential to improve the care for epilepsy patients. AEDs are associated with alterations in thyroid hormone metabolism. Thyroid function monitoring is indicated in patients on AEDs, especially those with refractory chronic epilepsy and those on polytherapy. We provide a practical guideline for thyroid function monitoring for the clinician taking care of patients on AEDs.

Euthyroid sick syndrome in older people

2001 ◽  
Vol 11 (1) ◽  
pp. 1-4
Author(s):  
Nadya Kagansky ◽  
Sari Tal ◽  
Shmuel Levy
Keyword(s):  
Thyroid Hormone ◽  
Older People ◽  
Thyroid Function ◽  
Clinical Evidence ◽  
Thyroid Function Tests ◽  
Hormone Metabolism ◽  
Euthyroid Sick Syndrome ◽  
Thyroid Hormone Metabolism ◽  
Function Tests ◽  
Altered Thyroid

The term euthyroid sick syndrome (ESS) is used to describe abnormalities in thyroid function tests that are observed in patients with systemic non-thyroid illness. Despite these abnormalities, there is usually little clinical evidence of hypothyroidism. Patients with ESS are generally considered to have altered thyroid hormone metabolism and to be euthyroid.

scholarly journals Thyroid function in rats with iodine deficiency is not further impaired by concurrent, marginal zinc deficiency

1993 ◽  
Vol 70 (2) ◽  
pp. 585-592 ◽  
Author(s):  
John G. G. Smit ◽  
Daan Van Der Heide ◽  
Gerrit Van Tintelen ◽  
Anton C. Beynen
Keyword(s):  
Body Weight ◽  
Thyroid Hormone ◽  
Thyroid Function ◽  
Body Weight Gain ◽  
Male Rats ◽  
Zn Deficiency ◽  
Hormone Metabolism ◽  
Thyroid Hormone Metabolism ◽  
Marginal Zinc Deficiency ◽  
Thyroid Hormone Levels

The hypothesis tested was that Zn deficiency aggravates impaired thyroid function as induced by I deficiency. In two separate experiments male rats were fed on diets either deficient in Zn or in I, or deficient in both. An identical, restricted amount of food was given to each rat so that body-weight gain of the experimental groups was comparable. Zn deficiency was evidenced by reduced tibial Zn concentrations. I deficiency was evidenced by goitre, reduced urinary I excretion, reduced plasma thyroxine concentrations and reduced absolute amounts and concentrations of thyroxine in the thyroid. Zn deficiency had no effect on the raised thyroid weight as induced by I deficiency. Zn restriction from 184 μmol Zn/kg diet to 31 μmol Zn/kg diet, hut not to 92 μmol Zn/kg diet, significantly lowered plasma thyroxine concentration. There were no interrelated effects of Zn and I deficiencies on thyroid hormone levels. These results indicate that marginal Zn deficiency does not influence thyroid hormone metabolism in I deficiency.

scholarly journals Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

2009 ◽  
Vol 160 (3) ◽  
pp. 331-336 ◽  
Author(s):  
Frédéric Illouz ◽  
Sandrine Laboureau-Soares ◽  
Séverine Dubois ◽  
Vincent Rohmer ◽  
Patrice Rodien
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Thyroid Function ◽  
Tyrosine Kinases ◽  
Kinase Inhibitors ◽  
Thyroid Function Tests ◽  
Hormone Regulation ◽  
Clinical Observations ◽  
Function Tests ◽  
First Case

Tyrosine kinase inhibitors (TKI) belong to new molecular multi-targeted therapies that are approved for the treatment of haematological and solid tumours. They interact with a large variety of protein tyrosine kinases involved in oncogenesis. In 2005, the first case of hypothyroidism was described and since then, some data have been published and have confirmed that TKI can affect the thyroid function tests (TFT). This review analyses the present clinical and fundamental findings about the effects of TKI on the thyroid function. Various hypotheses have been proposed to explain the effect of TKI on the thyroid function but those are mainly based on clinical observations. Moreover, it appears that TKI could alter the thyroid hormone regulation by mechanisms that are specific to each molecule. The present propositions for the management of TKI-induced hypothyroidism suggest that we assess the TFT of the patients regularly before and during the treatment by TKI. Thus, a better approach of patients with TKI-induced hypothyroidism could improve their quality of life.

Interference of dimethyl α-(dimethoxyphosphinyl) p-chlorobenzyl phosphate (SR-202) in thyroid hormone. metabolism: evidence of inhibition of monodeiodination

1987 ◽  
Vol 112 (1) ◽  
pp. 171-175 ◽  
Author(s):  
C. Liniger ◽  
D. Pometta ◽  
A. G. Burger
Keyword(s):  
Thyroid Hormone ◽  
Thyroid Hormones ◽  
Thyroid Function ◽  
Clinical Investigation ◽  
Compelling Evidence ◽  
Hormone Metabolism ◽  
Thyroid Hormone Metabolism ◽  
Peripheral Conversion

ABSTRACT SR-202 is a non-iodinated potential lipid-altering agent. When administered (100 mg) three times per day for 3 days to six euthyroid subjects it was associated with a 30 ± 3% (mean ± s.e.m.) fall in 3,3′,5-tri-iodothyronine(T3)(P < 0·001), a reciprocal 104 ± 14% rise in 3,3′,5′-tri-iodothyronine (reverse T3, rT3) (P < 0·01), and a 37 ± 7% rise in thyroxine (T4) (P < 0·001). Basal and TRH-stimulated TSH did not change. These results suggested that SR-202 was acting as an inhibitor of the peripheral monodeiodination of T4 to T3. During a second study the same subjects received the same dose of SR-202 for a further 3 days following 15 days of progressive substitutive treatment with l-T4, which they continued to take at 200 μg/day until the end of the study. Despite higher levels of thyroid hormones in the substituted subjects, similar results were observed, serum T3 falling by 40 ± 2% (P < 0·001), serum rT3 and T4 rising by 168 ± 24% (P < 0·01) and 37 ± 9% (P < 0·01) respectively. These changes provide compelling evidence that SR-202 is an inhibitor of the peripheral conversion of T4 to T3 that acts on thyroid hormone metabolism without provoking a counter-regulatory pituitary response. It might prove to be a useful tool for the clinical investigation of thyroid function. J. Endocr. (1987) 112, 171–175

scholarly journals ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors

2014 ◽  
Vol 171 (3) ◽  
pp. R91-R99 ◽  
Author(s):  
Frédéric Illouz ◽  
Doreen Braun ◽  
Claire Briet ◽  
Ulrich Schweizer ◽  
Patrice Rodien
Keyword(s):  
Side Effects ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Thyroid Function ◽  
Kinase Inhibitors ◽  
Thyroid Function Tests ◽  
Cancer Drugs ◽  
Function Tests ◽  
Anti Cancer ◽  
Thyroid Dysfunctions

Tyrosine kinase inhibitors (TKIs) are currently used by most oncologists. Among their side effects, thyroid dysfunctions are nowadays clearly observed. Whereas changes in thyroid function tests have been originally described with sunitinib, we now know that many TKIs can induce hypothyroidism and hyperthyroidism. In this study, the various molecules implicated in thyroid dysfunctions are analysed and the latest data on physiopathological mechanisms are approached in order to propose a strategy of thyroid monitoring of patients on TKI therapy.

Sign in / Sign up

Export Citation Format

Share Document